Privo Technologies is honored to receive a Phase 1 award for $220,000 from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program.
Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future oral... read more
PEABODY, Mass., Sept. 24, 2020 -- Privo Technologies, Inc. ("Privo"), a biopharmaceutical company focused on breakthrough localized treatments for tough to treat mucosal... read more
Peabody, MA — Privo Technologies, Inc. (“Privo”, “the Company”), a clinical stage biopharmaceutical company focused on optimizing state-of-the-art oncology treatments announced... read more
The Salisbury Award Competition is a set of competitions participated in by investigators at major cancer research institutions and/or scientists at... read more
Privo CEO, Dr. Manijeh Goldberg, is invited to speak at the BioNetwork Partnering Summit. read more
Privo Technologies, Inc. is pleased to announce that it has received IRB approval for its CLN-004 study from WCG... read more
Privo Technologies has been awarded ~$2 million in funding from the FDA through its Office of Orphan Product Development (OOPD)... read more
Peabody, MA– Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more
Privo Technologies (Privo) has been selected for the prestigious Phase IIB Bridge Award from the National Cancer Institute (NCI). The NCI SBIR... read more
Privo Technologies is honored to receive a Phase 2 award for $2M from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more
- © UX Strategy & Digital Branding